FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136162> ?p ?o ?g. }

• W4324136162 endingPage "15" @default.
• W4324136162 startingPage "15" @default.
• W4324136162 abstract "15 Background: In ARASENS (NCT02799602), DARO plus ADT and DOC significantly reduced the risk of death by 32.5% (HR 0.68; 95% CI: 0.57–0.80; P<0.0001) vs placebo (PBO) + ADT + DOC in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC), with similar overall incidences of treatment-emergent adverse events (TEAEs) between groups. The effect of DARO on overall survival (OS) was consistent across prespecified subgroups, including de novo and recurrent disease. For pts with mHSPC, outcomes based on disease volume and risk provide additional information to clinicians. Methods: Pts with mHSPC were randomized 1:1 to DARO 600 mg twice daily or PBO, with ADT + DOC. High-volume disease was defined as visceral metastases and/or ≥4 bone metastases with ≥1 beyond the vertebral column/pelvis (CHAARTED criteria). High-risk disease was defined as ≥2 risk factors: Gleason score ≥8, ≥3 bone lesions, and presence of measurable visceral metastasis (LATITUDE criteria). OS for these subgroups was assessed using an unstratified Cox regression model. Results: Of 1305 pts in the full analysis set, 1005 (77%) had high-volume disease, 912 (70%) had high-risk disease, 300 (23%) had low-volume disease, and 393 (30%) had low-risk disease. DARO + ADT + DOC prolonged OS regardless of high- or low-volume disease with HRs of 0.69 and 0.68 vs PBO + DOC + ADT, respectively. OS benefit of DARO vs PBO was also similar for pts with high- or low-risk disease. DARO improved clinically relevant secondary endpoints vs PBO in high/low-volume and risk subgroups, with HRs generally in the range of those observed in the overall population. Incidences of TEAEs were consistent with the overall ARASENS population across subgroups by high/low volume and high/low risk. Conclusions: In pts with mHSPC, the benefits of early treatment intensification with DARO + ADT + DOC on OS and key pt-relevant secondary efficacy endpoints vs PBO + ADT + DOC were similar in patients with high- and low-volume as well as high- and low-risk mH+SPC. The favorable safety profile of DARO was reconfirmed in high/low-volume and high/low-risk populations. DARO + ADT + DOC sets a new standard of care for pts with mHSPC. Clinical trial information: NCT02799602 . [Table: see text]" @default.
• W4324136162 created "2023-03-15" @default.
• W4324136162 creator A5003975247 @default.
• W4324136162 creator A5004503139 @default.
• W4324136162 creator A5004985848 @default.
• W4324136162 creator A5007779528 @default.
• W4324136162 creator A5017925159 @default.
• W4324136162 creator A5020692060 @default.
• W4324136162 creator A5021616410 @default.
• W4324136162 creator A5024848633 @default.
• W4324136162 creator A5040519604 @default.
• W4324136162 creator A5041126882 @default.
• W4324136162 creator A5044273966 @default.
• W4324136162 creator A5047408883 @default.
• W4324136162 creator A5053347862 @default.
• W4324136162 creator A5053749991 @default.
• W4324136162 creator A5071178428 @default.
• W4324136162 creator A5081062296 @default.
• W4324136162 creator A5083442694 @default.
• W4324136162 creator A5088518998 @default.
• W4324136162 creator A5090618504 @default.
• W4324136162 date "2023-02-20" @default.
• W4324136162 modified "2023-09-30" @default.
• W4324136162 title "Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study." @default.
• W4324136162 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.15" @default.
• W4324136162 hasPublicationYear "2023" @default.
• W4324136162 type Work @default.
• W4324136162 citedByCount "2" @default.
• W4324136162 countsByYear W43241361622023 @default.
• W4324136162 crossrefType "journal-article" @default.
• W4324136162 hasAuthorship W4324136162A5003975247 @default.
• W4324136162 hasAuthorship W4324136162A5004503139 @default.
• W4324136162 hasAuthorship W4324136162A5004985848 @default.
• W4324136162 hasAuthorship W4324136162A5007779528 @default.
• W4324136162 hasAuthorship W4324136162A5017925159 @default.
• W4324136162 hasAuthorship W4324136162A5020692060 @default.
• W4324136162 hasAuthorship W4324136162A5021616410 @default.
• W4324136162 hasAuthorship W4324136162A5024848633 @default.
• W4324136162 hasAuthorship W4324136162A5040519604 @default.
• W4324136162 hasAuthorship W4324136162A5041126882 @default.
• W4324136162 hasAuthorship W4324136162A5044273966 @default.
• W4324136162 hasAuthorship W4324136162A5047408883 @default.
• W4324136162 hasAuthorship W4324136162A5053347862 @default.
• W4324136162 hasAuthorship W4324136162A5053749991 @default.
• W4324136162 hasAuthorship W4324136162A5071178428 @default.
• W4324136162 hasAuthorship W4324136162A5081062296 @default.
• W4324136162 hasAuthorship W4324136162A5083442694 @default.
• W4324136162 hasAuthorship W4324136162A5088518998 @default.
• W4324136162 hasAuthorship W4324136162A5090618504 @default.
• W4324136162 hasConcept C121608353 @default.
• W4324136162 hasConcept C126322002 @default.
• W4324136162 hasConcept C143998085 @default.
• W4324136162 hasConcept C2777899217 @default.
• W4324136162 hasConcept C2779134260 @default.
• W4324136162 hasConcept C2780192828 @default.
• W4324136162 hasConcept C2781190966 @default.
• W4324136162 hasConcept C50382708 @default.
• W4324136162 hasConcept C71924100 @default.
• W4324136162 hasConceptScore W4324136162C121608353 @default.
• W4324136162 hasConceptScore W4324136162C126322002 @default.
• W4324136162 hasConceptScore W4324136162C143998085 @default.
• W4324136162 hasConceptScore W4324136162C2777899217 @default.
• W4324136162 hasConceptScore W4324136162C2779134260 @default.
• W4324136162 hasConceptScore W4324136162C2780192828 @default.
• W4324136162 hasConceptScore W4324136162C2781190966 @default.
• W4324136162 hasConceptScore W4324136162C50382708 @default.
• W4324136162 hasConceptScore W4324136162C71924100 @default.
• W4324136162 hasIssue "6_suppl" @default.
• W4324136162 hasLocation W43241361621 @default.
• W4324136162 hasOpenAccess W4324136162 @default.
• W4324136162 hasPrimaryLocation W43241361621 @default.
• W4324136162 hasRelatedWork W2060708716 @default.
• W4324136162 hasRelatedWork W2403920140 @default.
• W4324136162 hasRelatedWork W2588988563 @default.
• W4324136162 hasRelatedWork W2770702948 @default.
• W4324136162 hasRelatedWork W2776356588 @default.
• W4324136162 hasRelatedWork W2793295628 @default.
• W4324136162 hasRelatedWork W2890184401 @default.
• W4324136162 hasRelatedWork W3089313947 @default.
• W4324136162 hasRelatedWork W3132581442 @default.
• W4324136162 hasRelatedWork W785005902 @default.
• W4324136162 hasVolume "41" @default.
• W4324136162 isParatext "false" @default.
• W4324136162 isRetracted "false" @default.
• W4324136162 workType "article" @default.